175 related articles for article (PubMed ID: 24887406)
21. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
[TBL] [Abstract][Full Text] [Related]
22. Barley sprout extracts reduce hepatic lipid accumulation in ethanol-fed mice by activating hepatic AMP-activated protein kinase.
Kim YJ; Hwang SH; Jia Y; Seo WD; Lee SJ
Food Res Int; 2017 Nov; 101():209-217. PubMed ID: 28941686
[TBL] [Abstract][Full Text] [Related]
23. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
[TBL] [Abstract][Full Text] [Related]
24. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
[TBL] [Abstract][Full Text] [Related]
25. 3-N-butylphthalide protects against high-fat-diet-induced obesity in C57BL/6 mice and increases metabolism in lipid-accumulating cells.
Lu KY; Lin SZ; Primus Dass KT; Lin WJ; Liu SP; Harn HJ
Biomed Pharmacother; 2021 Jul; 139():111687. PubMed ID: 34243611
[TBL] [Abstract][Full Text] [Related]
26. Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism.
Suguro R; Pang XC; Yuan ZW; Chen SY; Zhu YZ; Xie Y
Pharmacol Res; 2020 Jan; 151():104519. PubMed ID: 31706011
[TBL] [Abstract][Full Text] [Related]
27. Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models.
Miyashita T; Toyoda Y; Tsuneyama K; Fukami T; Nakajima M; Yokoi T
J Toxicol Sci; 2012; 37(5):931-42. PubMed ID: 23038002
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of mitochondrial β-oxidation by miR-107 promotes hepatic lipid accumulation and impairs glucose tolerance in vivo.
Bhatia H; Pattnaik BR; Datta M
Int J Obes (Lond); 2016 May; 40(5):861-9. PubMed ID: 26499439
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
Cai Q; Bensen M; Greene R; Kirchner J
Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the liver lipidome reveals insights into the protective effect of exercise on high-fat diet-induced hepatosteatosis in mice.
Jordy AB; Kraakman MJ; Gardner T; Estevez E; Kammoun HL; Weir JM; Kiens B; Meikle PJ; Febbraio MA; Henstridge DC
Am J Physiol Endocrinol Metab; 2015 May; 308(9):E778-91. PubMed ID: 25714675
[TBL] [Abstract][Full Text] [Related]
31. Fatty liver and transaminase changes with adjuvant tamoxifen therapy.
Liu CL; Huang JK; Cheng SP; Chang YC; Lee JJ; Liu TP
Anticancer Drugs; 2006 Jul; 17(6):709-13. PubMed ID: 16917217
[TBL] [Abstract][Full Text] [Related]
32. Cooked rice inhibits hepatic fat accumulation by regulating lipid metabolism-related gene expression in mice fed a high-fat diet.
Choi WH; Um MY; Ahn J; Jung CH; Ha TY
J Med Food; 2014 Jan; 17(1):36-42. PubMed ID: 24456353
[TBL] [Abstract][Full Text] [Related]
33. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver.
Gudbrandsen OA; Rost TH; Berge RK
J Lipid Res; 2006 Oct; 47(10):2223-32. PubMed ID: 16864897
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen-induced fatty liver in patients with breast cancer.
Ogawa Y; Murata Y; Nishioka A; Inomata T; Yoshida S
Lancet; 1998 Mar; 351(9104):725. PubMed ID: 9504521
[No Abstract] [Full Text] [Related]
35. Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation.
Fedor DM; Adkins Y; Mackey BE; Kelley DS
Metab Syndr Relat Disord; 2012 Jun; 10(3):175-80. PubMed ID: 22242926
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.
Nemoto Y; Saibara T; Ogawa Y; Zhang T; Xu N; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
Intern Med; 2002 May; 41(5):345-50. PubMed ID: 12058881
[TBL] [Abstract][Full Text] [Related]
37. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide.
Imai Y; Varela GM; Jackson MB; Graham MJ; Crooke RM; Ahima RS
Gastroenterology; 2007 May; 132(5):1947-54. PubMed ID: 17484887
[TBL] [Abstract][Full Text] [Related]
38. Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in mice.
Tanaka S; Yamamoto H; Nakahashi O; Kagawa T; Ishiguro M; Masuda M; Kozai M; Ikeda S; Taketani Y; Takeda E
Nutr Res; 2013 Jul; 33(7):586-93. PubMed ID: 23827134
[TBL] [Abstract][Full Text] [Related]
39. Protective effect of lodoxamide on hepatic steatosis through GPR35.
Nam SY; Park SJ; Im DS
Cell Signal; 2019 Jan; 53():190-200. PubMed ID: 30304698
[TBL] [Abstract][Full Text] [Related]
40. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients.
Chang HT; Pan HJ; Lee CH
Clin Breast Cancer; 2018 Aug; 18(4):e677-e685. PubMed ID: 29287963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
